Sinco Pharmaceutical Holdings (HKSE:06833) Shares Outstanding (EOP): 2,033 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06833 Sinco Pharmaceutical Holdings Ltd HKSE:06833
44 GF Score
Price HK$0.17
GF Value HK$0.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sinco Pharmaceutical Holdings Shares Outstanding (EOP)?

Sinco Pharmaceutical Holdings HKSE:06833 -0.60% 44 Shares Outstanding (EOP) is 2,033 Mil as of Dec. 2025. GuruFocus rates HKSE:06833 with a GF Score™ of 44/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sinco Pharmaceutical Holdings's shares outstanding for the quarter that ended in Dec. 2025 was 2,033 Mil.

Sinco Pharmaceutical Holdings's quarterly shares outstanding stayed the same from Jun. 2025 (2,033 Mil) to Dec. 2025 (2,033 Mil).

Sinco Pharmaceutical Holdings's annual shares outstanding stayed the same from Dec. 2024 (2,033 Mil) to Dec. 2025 (2,033 Mil).


Sinco Pharmaceutical Holdings  (HKSE:06833) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Sinco Pharmaceutical Holdings Shares Outstanding (EOP) Related Terms


Sinco Pharmaceutical Holdings Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Sinco Pharmaceutical Holdings's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinco Pharmaceutical Holdings Shares Outstanding (EOP) Chart

Sinco Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,872.89 2,032.89 2,032.89 2,032.89 2,032.89

Sinco Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,032.89 2,032.89 2,032.89 2,032.89 2,032.89

HKSE:06833 vs MCK, COR, CAH: Shares Outstanding (EOP) Comparison

For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinco Pharmaceutical Holdings Shares Outstanding (EOP) vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Sinco Pharmaceutical Holdings's Shares Outstanding (EOP) falls into.


HKSE:06833
44GF Score
Sinco Pharmaceutical Holdings Ltd HKSE:06833
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinco Pharmaceutical Holdings Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 2,033 Mil mean?
Sinco Pharmaceutical Holdings (HKSE:06833) has a Shares Outstanding (EOP) of 2,033 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Sinco Pharmaceutical Holdings and its competitors.
Is Sinco Pharmaceutical Holdings' Shares Outstanding (EOP) too high?
Sinco Pharmaceutical Holdings' current Shares Outstanding (EOP) is 2,033 Mil. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' Shares Outstanding (EOP) compare to MCK and COR?
Sinco Pharmaceutical Holdings' Shares Outstanding (EOP) of 2,033 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Distribution company?
A good Shares Outstanding (EOP) depends on the Medical Distribution industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Sinco Pharmaceutical Holdings and its competitors. Sinco Pharmaceutical Holdings's current Shares Outstanding (EOP) is 2,033 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current Shares Outstanding (EOP) is 2,033 Mil. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current Shares Outstanding (EOP) is 2,033 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?

Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued. The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19. GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.

Key valuation signals for HKSE:06833:

  • Shares Outstanding (EOP): 2,033 Mil
  • GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sinco Pharmaceutical Holdings Business Description

Address No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score

Get the complete analysis for HKSE:06833

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.17
Price
HK$0.19
GF Value